Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk

Peiyu Xie, Fan Yan Wei, Shoji Hirata, Taku Kaitsuka, Tsutomu Suzuki, Takeo Suzuki, Kazuhito Tomizawa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: Genetic variants in the human CDKAL1 (CDK5 regulatory subunit associated protein 1-like 1) gene have been associated with reduced insulin secretion and type 2 diabetes (T2D).CDKAL1is a methylthiotransferase that catalyzes 2-methylthio (ms2) modification of the adenine at position 37 (A37) of cytoplasmic tRNALys- (UUU). We investigated the ms 2-modification level of tRNALys(UUU) as a direct readout of CDKAL1 enzyme activity in human samples. METHOD: We developed a quantitative PCR (qPCR)-based method to measure ms2 modification. tRNA Lys(UUU) was reverse-transcribed with 2 unique primers: Reverse primer r1 was designed to anneal to the middle of this tRNA, including the nucleotide at A37, and reverse primer r2 was designed to anneal to the region downstream (3) of A37. Subsequent qPCR was performed to detect the corresponding transcribed cDNAs. RESULTS: The efficiency of reverse transcription of tRNALys(UUU) was ms2-modification dependent. The relative difference in threshold cycle number obtained with the r1 or r2 primer yielded the ms2-modification level in tRNALys(UUU) precisely as predicted by an original mathematical model. The method was capable of measuring ms2-modification levels in tRNALys(UUU) in total RNA isolated from human peripheral blood samples, revealing that the ms 2-modification rate in tRNALys(UUU) was decreased in individuals carrying the CDKAL1 genotype associated with T2D. In addition, the ms2-modification level was correlated with insulin secretion. CONCLUSIONS: The results point to the critical role of ms2 modification in T2D and to a potential clinical use of a simple and high-throughput method for assessing T2D risk.

Original languageEnglish
Pages (from-to)1604-1612
Number of pages9
JournalClinical Chemistry
Volume59
Issue number11
DOIs
Publication statusPublished - Nov 1 2013
Externally publishedYes

Fingerprint

RNA, Transfer, Lys
Medical problems
Transfer RNA
Type 2 Diabetes Mellitus
Polymerase Chain Reaction
Insulin
Enzyme activity
Adenine
Transcription
Human Activities
Reverse Transcription
Blood
Theoretical Models
Nucleotides
Complementary DNA
Genes
Genotype
Throughput
RNA
Mathematical models

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Xie, P., Wei, F. Y., Hirata, S., Kaitsuka, T., Suzuki, T., Suzuki, T., & Tomizawa, K. (2013). Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk. Clinical Chemistry, 59(11), 1604-1612. https://doi.org/10.1373/clinchem.2013.210401

Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk. / Xie, Peiyu; Wei, Fan Yan; Hirata, Shoji; Kaitsuka, Taku; Suzuki, Tsutomu; Suzuki, Takeo; Tomizawa, Kazuhito.

In: Clinical Chemistry, Vol. 59, No. 11, 01.11.2013, p. 1604-1612.

Research output: Contribution to journalArticle

Xie, P, Wei, FY, Hirata, S, Kaitsuka, T, Suzuki, T, Suzuki, T & Tomizawa, K 2013, 'Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk', Clinical Chemistry, vol. 59, no. 11, pp. 1604-1612. https://doi.org/10.1373/clinchem.2013.210401
Xie, Peiyu ; Wei, Fan Yan ; Hirata, Shoji ; Kaitsuka, Taku ; Suzuki, Tsutomu ; Suzuki, Takeo ; Tomizawa, Kazuhito. / Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk. In: Clinical Chemistry. 2013 ; Vol. 59, No. 11. pp. 1604-1612.
@article{d3bbd9fa2ea7497f866a725d805514fb,
title = "Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk",
abstract = "BACKGROUND: Genetic variants in the human CDKAL1 (CDK5 regulatory subunit associated protein 1-like 1) gene have been associated with reduced insulin secretion and type 2 diabetes (T2D).CDKAL1is a methylthiotransferase that catalyzes 2-methylthio (ms2) modification of the adenine at position 37 (A37) of cytoplasmic tRNALys- (UUU). We investigated the ms 2-modification level of tRNALys(UUU) as a direct readout of CDKAL1 enzyme activity in human samples. METHOD: We developed a quantitative PCR (qPCR)-based method to measure ms2 modification. tRNA Lys(UUU) was reverse-transcribed with 2 unique primers: Reverse primer r1 was designed to anneal to the middle of this tRNA, including the nucleotide at A37, and reverse primer r2 was designed to anneal to the region downstream (3) of A37. Subsequent qPCR was performed to detect the corresponding transcribed cDNAs. RESULTS: The efficiency of reverse transcription of tRNALys(UUU) was ms2-modification dependent. The relative difference in threshold cycle number obtained with the r1 or r2 primer yielded the ms2-modification level in tRNALys(UUU) precisely as predicted by an original mathematical model. The method was capable of measuring ms2-modification levels in tRNALys(UUU) in total RNA isolated from human peripheral blood samples, revealing that the ms 2-modification rate in tRNALys(UUU) was decreased in individuals carrying the CDKAL1 genotype associated with T2D. In addition, the ms2-modification level was correlated with insulin secretion. CONCLUSIONS: The results point to the critical role of ms2 modification in T2D and to a potential clinical use of a simple and high-throughput method for assessing T2D risk.",
author = "Peiyu Xie and Wei, {Fan Yan} and Shoji Hirata and Taku Kaitsuka and Tsutomu Suzuki and Takeo Suzuki and Kazuhito Tomizawa",
year = "2013",
month = "11",
day = "1",
doi = "10.1373/clinchem.2013.210401",
language = "English",
volume = "59",
pages = "1604--1612",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "11",

}

TY - JOUR

T1 - Quantitative PCR measurement of tRNA 2-Methylthio modification for assessing type 2 diabetes risk

AU - Xie, Peiyu

AU - Wei, Fan Yan

AU - Hirata, Shoji

AU - Kaitsuka, Taku

AU - Suzuki, Tsutomu

AU - Suzuki, Takeo

AU - Tomizawa, Kazuhito

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: Genetic variants in the human CDKAL1 (CDK5 regulatory subunit associated protein 1-like 1) gene have been associated with reduced insulin secretion and type 2 diabetes (T2D).CDKAL1is a methylthiotransferase that catalyzes 2-methylthio (ms2) modification of the adenine at position 37 (A37) of cytoplasmic tRNALys- (UUU). We investigated the ms 2-modification level of tRNALys(UUU) as a direct readout of CDKAL1 enzyme activity in human samples. METHOD: We developed a quantitative PCR (qPCR)-based method to measure ms2 modification. tRNA Lys(UUU) was reverse-transcribed with 2 unique primers: Reverse primer r1 was designed to anneal to the middle of this tRNA, including the nucleotide at A37, and reverse primer r2 was designed to anneal to the region downstream (3) of A37. Subsequent qPCR was performed to detect the corresponding transcribed cDNAs. RESULTS: The efficiency of reverse transcription of tRNALys(UUU) was ms2-modification dependent. The relative difference in threshold cycle number obtained with the r1 or r2 primer yielded the ms2-modification level in tRNALys(UUU) precisely as predicted by an original mathematical model. The method was capable of measuring ms2-modification levels in tRNALys(UUU) in total RNA isolated from human peripheral blood samples, revealing that the ms 2-modification rate in tRNALys(UUU) was decreased in individuals carrying the CDKAL1 genotype associated with T2D. In addition, the ms2-modification level was correlated with insulin secretion. CONCLUSIONS: The results point to the critical role of ms2 modification in T2D and to a potential clinical use of a simple and high-throughput method for assessing T2D risk.

AB - BACKGROUND: Genetic variants in the human CDKAL1 (CDK5 regulatory subunit associated protein 1-like 1) gene have been associated with reduced insulin secretion and type 2 diabetes (T2D).CDKAL1is a methylthiotransferase that catalyzes 2-methylthio (ms2) modification of the adenine at position 37 (A37) of cytoplasmic tRNALys- (UUU). We investigated the ms 2-modification level of tRNALys(UUU) as a direct readout of CDKAL1 enzyme activity in human samples. METHOD: We developed a quantitative PCR (qPCR)-based method to measure ms2 modification. tRNA Lys(UUU) was reverse-transcribed with 2 unique primers: Reverse primer r1 was designed to anneal to the middle of this tRNA, including the nucleotide at A37, and reverse primer r2 was designed to anneal to the region downstream (3) of A37. Subsequent qPCR was performed to detect the corresponding transcribed cDNAs. RESULTS: The efficiency of reverse transcription of tRNALys(UUU) was ms2-modification dependent. The relative difference in threshold cycle number obtained with the r1 or r2 primer yielded the ms2-modification level in tRNALys(UUU) precisely as predicted by an original mathematical model. The method was capable of measuring ms2-modification levels in tRNALys(UUU) in total RNA isolated from human peripheral blood samples, revealing that the ms 2-modification rate in tRNALys(UUU) was decreased in individuals carrying the CDKAL1 genotype associated with T2D. In addition, the ms2-modification level was correlated with insulin secretion. CONCLUSIONS: The results point to the critical role of ms2 modification in T2D and to a potential clinical use of a simple and high-throughput method for assessing T2D risk.

UR - http://www.scopus.com/inward/record.url?scp=84887055526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887055526&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2013.210401

DO - 10.1373/clinchem.2013.210401

M3 - Article

C2 - 23974085

AN - SCOPUS:84887055526

VL - 59

SP - 1604

EP - 1612

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 11

ER -